A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives

Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
10/2006
10/11/2006	CN1278740C Contrast agent and improved contrast agent thereof
10/11/2006	CN1278690C 25-hydroxy vitamin D3 compositions
10/11/2006	CN1278688C oral dispersion pharmaceutical composition comprising ivabradine
10/11/2006	CN1278678C Pharmaceutical composition of fenofibrate with high biological utilizing rate and its preparation method
10/11/2006	CN1278675C Granular body containing polydroxy alkoxide acid ester and its preparation method
10/11/2006	CN1278672C Pharmaceutical composition for intramuscular injection containing loxoprofen
10/11/2006	CN1278626C Colorant for food and pharmaceuticals
10/10/2006	US7119195 Pharmaceutically acceptable starch
10/10/2006	US7119174 AURORA-1/2 (AUR1/2) antibodies or fragments thereof; humanized monoclonal antibodies; hybridomas; immunoassay; for treatment of cancer and screening cell growth inhibitors
10/10/2006	US7119124 Pharmaceutical compositions containing plasma protein
10/10/2006	US7119078 Administering a G-rich oligonucleotide that forms a G-quartet structure and inhibits DNA binding activity of a signal transducer and activator of transcription 3 (STAT3) protein; antiproliferative, anticarcinogenic, antitumor agents
10/10/2006	US7119074 Treatment of cancers, tumors and malignancies using amphiphilic prodrugs
10/10/2006	US7119066 Replacing cysteine 17 with alanine, glutamine 63 with arginine and a deletion of the terminal 15 amino acid residues; treatment of huntington's disease, obesity, and gestational or adult onset diabetes
10/10/2006	US7118765 Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms
10/10/2006	US7118763 Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
10/10/2006	US7118762 Controlling, stabilization blood, glucose concentration
10/10/2006	US7118376 System for the controlled delivery of an active material to a dental site
10/10/2006	CA2356391C Transdermal drug delivery system
10/10/2006	CA2336682C Compositions for rapid and non-irritating transdermal delivery of pharmaceutically active agents and methods for formulating such compositions and delivery thereof
10/10/2006	CA2323048C Poly(ethylene glycol) derivatives with proximal reactive groups
10/10/2006	CA2321909C Product and method to reduce stress induced immune suppression
10/10/2006	CA2307303C Prolonged-action eye drop
10/10/2006	CA2306333C Oral morphine multiparticulate formulation
10/10/2006	CA2291233C Compositions containing bergamottin for increasing the oral bioavailability of pharmaceutical agents
10/10/2006	CA2290521C Medicinal aerosol products
10/10/2006	CA2277952C A process for preparing polymeric microgels
10/10/2006	CA2231640C Liquid oral composition comprising a cationic bactericide and hydroxypropyl methyl cellulose
10/10/2006	CA2214418C Water-based topical cream containing nitroglycerin; method of preparation and use thereof
10/10/2006	CA2208849C Novel cyclodextrin derivatives and methods for the preparation thereof
10/10/2006	CA2189254C Modulated release from biocompatible polymers
10/05/2006	WO2006105384A1 Composition for treating dry eye and related methods of manufacture and methods of use
10/05/2006	WO2006105173A2 Oral delivery vehicle and material
10/05/2006	WO2006105148A2 Peg-poly(ortho ester) graft copolymers and pharmaceutical compositions
10/05/2006	WO2006105123A2 Peg-polyacetal diblock and triblock copolymers and pharmaceutical compositions
10/05/2006	WO2006105044A1 Suicidal mutant leishmania vaccine
10/05/2006	WO2006104852A2 Vegf antagonist formulations
10/05/2006	WO2006104530A1 Therapeutics targeted to renal cells
10/05/2006	WO2006104199A1 Liposome composition for induction of immunity
10/05/2006	WO2006103691A1 Stable pharmaceutical compositions of platinum (ii) antitumour agents
10/05/2006	WO2006103494A2 Antiviral bifunctional molecules, methods of construction and methods of treating virus-induced cancer therewith
10/05/2006	WO2006102965A1 Multiparticulate pharmaceutical form comprising pellets with a matrix which influences the delivery of a modulatory substance
10/05/2006	WO2006102854A1 A conjugate of biomacromolecule with bioreductive and preparative method thereof
10/05/2006	WO2006102800A1 Nano-micellar preparation of anthracycline antitumor antibiotics wrapped by the polyethylene glycols derivative of phosphatide
10/05/2006	WO2006102768A1 Colloidal solid lipid vehicle for pharmaceutical use
10/05/2006	WO2006102762A1 Glucose responsive microgels
10/05/2006	WO2006102752A1 Compositions for oral transmucosal delivery of metformin
10/05/2006	WO2006102748A1 Intravenous formulations of pyridoxal 5'-phosphate and method of preparation
10/05/2006	WO2006085335A3 Pharmaceutical composition of acid labile substances
10/05/2006	WO2006081553A3 ANTI-MUC1 α/ß ANTIBODIES
10/05/2006	WO2006026935A3 Pharmaceutical composition for rectal or vaginal application comprising a platinum complex
10/05/2006	WO2006026703A3 Chemical compounds
10/05/2006	WO2005092392A3 Conjugated psychotropic drugs and uses thereof
10/05/2006	WO2005042028A3 Il-13 conjugated to an immunogen and uses thereof
10/05/2006	WO2004016736A3 Nucleic acids and corresponding proteins entitled 202p5a5 useful in treatment and detection of cancer
10/05/2006	US20060223889 Veterinary aqueous injectable suspensions containing florfenicol
10/05/2006	US20060223865 Therapeutic combination
10/05/2006	US20060223784 Method and compositions for temporarily incapacitating subjects
10/05/2006	US20060223770 IRNA agents targeting VEGF
10/05/2006	US20060223767 Vector for gene therapy and method of quantifying target protein in mammal or cultured cells with the administration of the vector for gene therapy
10/05/2006	US20060223758 Treating treating angiogenic disease by administering therapeutically effective amount of compounds of the invention, for example, {(3R, 4S, 5S, 6R)-5-Methoxy-4-[(2R, 3R)-2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yloxycarbonylamino}-3-methyl-butyric acid methyl ester; stability
10/05/2006	US20060223746 Injecting an alpha v beta 3 and/or alpha v beta 5 inhibitor, sufficient to inhibit or reduce angiogenesis or neovascularization in the treated eye, into the sclera layer of the eye; (2S)-2-benzyloxycarboxamido-3-(2-guanidinomethyl-1,4-benzodioxan-6-yl)propionic acid
10/05/2006	US20060223740 Absorption enhancers such as e.g. bht, bha or propyl gallate
10/05/2006	US20060222766 Encapsulation system
10/05/2006	US20060222711 Composition of and method for preparing stable particles in a frozen aqueous matrix
10/05/2006	US20060222710 Composition of and method for preparing stable particles in a frozen aqueous matrix
10/05/2006	US20060222697 Hepatocyte delivery vehicle for delivery of a combination of recombinant human regular insulin and recombinant human insulin isophane to a mammal
10/05/2006	US20060222691 Composition for the transdermal delivery of fentanyl
10/05/2006	US20060222682 Nutraceutical Moringa composition
10/05/2006	US20060222677 Method of protecting sensitive molecules from a photo-polymerizing environment
10/05/2006	US20060222673 Injectable phosphatidylcholine preparations
10/05/2006	US20060222666 Clostridial toxin derivatives and methods for treating pain
10/05/2006	US20060222662 Composition to be administered to a living being and method for marking agents
10/05/2006	US20060222655 Compositions and methods for preventing and treating endotoxin-related diseases and conditions
10/05/2006	US20060222648 Graft-versus-host disease; inhibit secretion of Interferon-gamma (IFN-?) by lymphocytes or other immune cells in a mammal; inflammatory bowel disease is Crohn's disease, ulcerative colitis, or ileitis; KIM-1 (Kidney Injury Molecule-1)
10/05/2006	US20060222628 Gallium complexes of 3-hydroxy-4-pyrones to treat infection by intracellular prokaryotes and DNA viruses
10/05/2006	DE102005015286A1 Use of photosensitizer to carry pharmaceutical active agents to the corresponding destinations, for treatment of cancer, muscular degeneration and rheumatism
10/05/2006	CA2634038A1 Liposome composition for immune induction
10/05/2006	CA2603450A1 Compositions for oral transmucosal delivery of metformin
10/05/2006	CA2603334A1 Intravenous formulations of pyridoxal 5'-phosphate and method of preparation
10/05/2006	CA2601547A1 Peg-poly(ortho ester) graft copolymers and pharmaceutical compositions
10/05/2006	CA2601546A1 Peg-polyacetal diblock and triblock copolymers and pharmaceutical compositions
10/05/2006	CA2601339A1 Multiparticulate pharmaceutical form comprising pellets with a matrix which influences the delivery of a modulatory substance
10/05/2006	CA2600282A1 Multiparticulate pharmaceutical form comprising pellets with a substance having a modular effect in relation to active ingredient release
10/05/2006	CA2598711A1 Vegf antagonist formulations
10/04/2006	EP1707217A1 Process for preparing an alpha lipoic acid/cyclodextrin complex and product prepared
10/04/2006	EP1707205A2 Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
10/04/2006	EP1707196A1 Improved formulations of fenofibrate
10/04/2006	EP1706399A1 Polyethylene glycol conjugates of heterocycloalkyl carboxamido propanoic acids
10/04/2006	EP1706155A1 Polymeric micellar complexes and drug delivery vehicles thereof
10/04/2006	EP1706152A2 Particle-induced ghrelin immune response
10/04/2006	EP1706151A2 Method of protecting sensitive molecules from a photopolymerising environment
10/04/2006	EP1706150A1 Stable growth hormone liquid formulation
10/04/2006	EP1706149A2 Liposome composition for delivery of therapeutic agents
10/04/2006	EP1706148A2 Lipid-based dispersions useful for drug delivery
10/04/2006	EP1706145A1 Autoantibodies utilized as carrier agents for pharmaceutical compounds used in tumor imaging and cancer treatment
10/04/2006	EP1706128A1 Pharmaceutical compositions and methods for insulin treatment
10/04/2006	EP1706116A1 Pharmaceutical compositions
10/04/2006	EP1706098A2 Micellar systems useful for delivery of lipophilic or hydrophobic compounds
10/04/2006	EP1706097A2 Topically applied medicament for animals
10/04/2006	EP1706096A1 Consumer customized dosage forms

1 ... 808 809 810 811 812 813 814 815 816 817 818 819 820 821 822 823 824 825 826 827 828 ... 1712